Immunotherapy

The field of immuno-oncology continues to rapidly evolve as new insights to fight and treat cancer emerge. The fourth edition of Immunotherapy provides the most current overview of immuno-oncology in different cancer types and toxicities associated with immunotherapy. While immunotherapy has revolutionized the treatment landscape of several solid malignancies, several challenges still exist. Only a subset of patients derive clinical benefits; some do not respond at all, and others respond initially, only for their disease to progress later. Because these drugs can activate a broad range of immune cells, patients suffer from a unique set of side effects known as immune-related adverse events. As more immunotherapeutic agents are used in the clinic, it is important to provide updates about current and ongoing developments in the field to further research efforts and inform treatment decisions. The fourth edition will have a new focus on strategies to overcomethe challenges associated with immunotherapy. Chapters will discuss topics such as biomarkers of response, resistance mechanisms, role of imaging in predicting immune-related adverse events, and management of immune-related adverse events. Written by leading experts conducting cutting-edge research, readers will gain up-to-date knowledge on the current state and future of immunotherapy.

Provides up-to-date overview of current immunotherapeutic treatment options, strategies, and research efforts Discusses strategies to overcome the challenges associated with immunotherapy Presents cutting-edge research that may inform future developments in the field of immunotherapy

Autorentext
Dr. Aung Naing is a Professor in the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center and is also a Principal Investigator on immunotherapy-based clinical trials. Focusing on clinical translation of basic immunobiology, Dr. Naing's research interests are (1) identifying immunologic biomarkers of response to immunotherapy, (2) predicting primary and secondary resistance to immunotherapy, (3) developing immunotherapeutic strategies to overcome resistance, and (4) identifying predictive markers for immune-related adverse events (irAE) associated with immunotherapies.

Dr. Joud Hajjar is an Assistant Professor of Allergy and Immunology and serves as the service chief of adult allergy and immunology at Texas Children's Hospital. She is a member of the Basic and Clinical Immunology Interest group at the American Academy of Allergy Asthma and Immunology, and the Women in Clinical Immunology Committee at the Clinical Immunology Society. Dr. Hajjar's research interests are in inborn errors of immunity, microbiome in the immunocompromised host, and cancer immunotherapy.

Inhalt

Immune System in Action.- 2. Resistance to Immunotherapy: Mechanisms and Means for Overcoming.- 3. Immunotherapy for Melanoma.- 4. Immunotherapy in Lung Cancer: Are the promises of long-term benefit finally met?.- 5. Landscape of Immunotherapy in Genitourinary Malignancies.- 6. Immuno-oncology for Gynecologic Malignancies.- 7. Immunotherapy for Neuro-oncology.- 8. Immunotherapy in Gastrointestinal Malignancies.- 9. An update on immune based therapies in acute myeloid leukemia: 2021 and beyond!.- 10. CAR T-cells.- 11. Skin Reactions to Immune Checkpoint Inhibitors.- 12. Immunotherapy Mediated luminal Gastrointestinal toxicities.- 13. Hepatobiliary and Pancreatic Adverse Events .- 14. Pulmonary toxicities of immunotherapy.- 15. Immune checkpoint inhibitors (ICIs) related cardiotoxicity.- 16. Renal Toxicity.- 17. Immune-Related Oral, Otologic and Ocular Adverse Events.- 18. Neurologic Toxicities of Immunotherapy.- 19. Cancer Imaging in Immunotherapy.

<p